Kestra Medical Technologies Ltd. (KMTS) Receives a Buy from Stifel Nicolaus
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Kestra Medical Technologies (KMTS) with a $30 price target. The report notes KMTS has a Strong Buy consensus and $30 target. Additionally, TipRanks launched the RANK ETF, tracking its US Momentum Analysts Index of 50 large U.S. companies.
In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Kestra Medical Technologies Ltd., with a price target of $30.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Wise is an analyst with an average return of -1.5% and a 47.90% success rate. Wise covers the Healthcare sector, focusing on stocks such as Boston Scientific, Solventum Corporation, and Artivion.
Kestra Medical Technologies Ltd. has an analyst consensus of Strong Buy, with a price target consensus of $30.00.